Special Issue "Lipid Metabolism Disorders in Chronic Obstructive Pulmonary Disease and Atherosclerosis"

Dear Colleagues,

COPD is one of the most significant challenges in respiratory medicine. This disease demonstrates adverse trends in prevalence, as well as impacts on quality of life and prognosis. In turn, the clinical significance of atherosclerosis is emphasized by its heavy medical, economic and social burden on patients, society and health care systems in many countries. It is important to note that COPD and atherosclerosis often occur in the same patient, and in most cases, it is impossible to determine exactly which disease developed first. The diseases are often diagnosed late and can mutually worsen each other's course, affecting quality of life and prognosis. These and other data are bringing the comorbid courses of COPD and atherosclerosis to the attention of clinicians and researchers.

A growing amount of evidence suggests an immune and metabolic axis that links COPD and atherosclerosis in their comorbid development and courses. Lipid metabolism is part of this axis, and its disorders are one of the most important links in the complex chain of processes underlying the pathogenesis of both COPD and atherosclerosis. Indeed, the lungs have a unique lipid biology, disturbances of which can be caused by smoking. The development of the lipid theory of atherogenesis has expanded the understanding of the role of lipids from a simple morphological substrate of atherosclerotic deposits to a participant of many immune processes, the disorders of which are part of the pathogenesis of atherosclerosis. It should be noted that the keys to understanding many links in the pathogenesis of both the isolated and comorbid course of COPD and atherosclerosis are still largely unknown to clinicians and researchers.

Thus, this Special Issue focuses on original research and thorough reviews of recent advances in the metabolic and immune mechanisms underlying COPD and atherosclerosis. These articles can focus on various research aspects that will help to improve the understanding of the metabolic links and their pathophysiological and clinical significance.

Dr. Stanislav Kotlyarov
Dr. Xiaoyan Zhang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• COPD
• atherosclerosis
• comorbidity
• lipid metabolism
• lipid transport
• innate immune system
• inflammation
• immunometabolism